Table 1.
Patient and clinical characteristics
| No. | % | |
|---|---|---|
| No. | 94 | |
| Median age, years (range) | 61.5 (22–84) | |
| Gender | ||
| Female | 33 | 35 |
| Male | 61 | 65 |
| Bone marrow blasts, median/range | 4 (0–18) | |
| Peripheral blasts, median/range | 0 (0–11) | |
| Leukocytes, median/range (/µl) | 3,3 × 103 (0,7–26 × 103) | |
| Hemoglobin, median range (g/dl) | 9,5 (4,8–14,8 103) | |
| Platelets, median/range (/µl) | 80 × 103 (6–670 × 103) | |
| WHO 2016 classification | ||
| MDS del5q | 7 | 7 |
| MDS-U | 3 | 3 |
| MDS SLD | 3 | 3 |
| MDS RS SLD | 1 | 1 |
| MDS MLD | 39 | 41 |
| MDS EB1 | 16 | 17 |
| MDS EB2 | 25 | 27 |
| Primary MDS | 86 | 91 |
| Therapy related MDS | 8 | 9 |
| IPSS-R | ||
| Very low | 3 | 3 |
| Low | 28 | 31 |
| Intermediate | 28 | 30 |
| High | 14 | 14 |
| Very high | 21 | 22 |
| Karyotype | ||
| Normal | 41 | 44 |
| Abnormal | 52 | 55 |
| Complex | 21 | 22 |
| Missing | 1 | 1 |
| Cytogenetic risk groupa | ||
| Very good | 4 | 4 |
| Good | 52 | 55 |
| Intermediate | 6 | 6 |
| Poor | 22 | 23 |
| Very poor | 9 | 10 |
| Missing | 1 | 1 |
| Presence of certain molecular mutationsb (ASXL1, EZH2, TET2, TP53, DNMT3A, RUNX1) | 24 | 26 |
| Treatment | ||
| Transfusion only | 6 | 7 |
| Growth factors | 22 | 23 |
| Lenalidomide | 7 | 7 |
| HMA | 10 | 11 |
| Intensive chemotherapy | 5 | 5 |
| Allogeneic stem-cell transplantation | 44 | 47 |
No. number, WHO World Health Organization, MDS SLD MDS with single lineage dysplasia, MDS RS SLD MDS with ring sideroblasts and single lineage dysplasia, MDS MLD MDS with multilineage dysplasia, MDS EB1 MDS with excess blasts 1, MDS EB2 MDS with excess of blasts 2, MDS del5q myelodysplastic syndrome with isolated del(5q), MDS-U myelodysplastic syndrome unclassifiable, HMA hypomethylating agents
aAccording to IPSS-R
bInformation based on results from clinical routine, but not on a comprehensive molecular analysis of all patients